Table 1 Outline of study design Group .... | American Society of Hematology

Table 1

Outline of study design

Group	MMF, oral administration		Sirolimus, oral administration		Daclizumab, intravenous administration
Group	Dose/schedule	Duration	Dose/schedule	Duration	Dose/schedule
1	NA	NA	NA	NA	NA
2	25 mg/kg twice daily	From d −7 to d 70	2 mg/kg once daily	From d +3 to d 70	2 mg/kg at d −1; 1 mg/kg at d 15
3	25 mg/kg twice daily	From d −7 to d 70	4 mg/kg once daily; 2 mg/kg once daily	From d 1 to d 7; from d 8 to d 70	NA; NA

Group	MMF, oral administration		Sirolimus, oral administration		Daclizumab, intravenous administration
Group	Dose/schedule	Duration	Dose/schedule	Duration	Dose/schedule
1	NA	NA	NA	NA	NA
2	25 mg/kg twice daily	From d −7 to d 70	2 mg/kg once daily	From d +3 to d 70	2 mg/kg at d −1; 1 mg/kg at d 15
3	25 mg/kg twice daily	From d −7 to d 70	4 mg/kg once daily; 2 mg/kg once daily	From d 1 to d 7; from d 8 to d 70	NA; NA

For each group (n = 3), the AAV2-hF.IX vector at a dose of 8 × 10¹² vg/kg was used.

NA indicates not applicable.